<List><item><source>MED</source><extId>28712033</extId><pmcid>PMC5626801</pmcid><annotations><annotation><prefix>aherparepvecMelanoma</prefix><exact>NCT00769704</exact><postfix>3Talimogene laherpar</postfix><tags><tag><name>NCT00769704</name><uri>http://identifiers.org/clinicaltrials/NCT00769704</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-e3cb122f4e70364d14ac63312eddc211</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>herparepvecMelanoma </prefix><exact>NCT02297529</exact><postfix> 3bTalimogene laherp</postfix><tags><tag><name>NCT02297529</name><uri>http://identifiers.org/clinicaltrials/NCT02297529</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-81834f89e62ff809c7aeb255373ced61</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>aherparepvecMelanoma</prefix><exact>NCT02147951</exact><postfix>3bTalimogene laherpa</postfix><tags><tag><name>NCT02147951</name><uri>http://identifiers.org/clinicaltrials/NCT02147951</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-1a30c6313c479f9a1777f385909950a6</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>aherparepvecMelanoma</prefix><exact>NCT00289016</exact><postfix>2Talimogene laherpar</postfix><tags><tag><name>NCT00289016</name><uri>http://identifiers.org/clinicaltrials/NCT00289016</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-b3507fae3b398266190a06151ea7787e</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>aherparepvecMelanoma</prefix><exact>NCT02366195</exact><postfix>2Talimogene laherpar</postfix><tags><tag><name>NCT02366195</name><uri>http://identifiers.org/clinicaltrials/NCT02366195</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-e071a517e37b787b9fe9a2c0d79eb53d</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>herparepvecMelanoma </prefix><exact>NCT02014441</exact><postfix> 2Talimogene laherpa</postfix><tags><tag><name>NCT02014441</name><uri>http://identifiers.org/clinicaltrials/NCT02014441</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-d613599d2e76e9bbfae39a30b8569fb9</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>herparepvecMelanoma </prefix><exact>NCT02211131</exact><postfix> 2Talimogene laherpa</postfix><tags><tag><name>NCT02211131</name><uri>http://identifiers.org/clinicaltrials/NCT02211131</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-e224170c9073b204d29d7818f6af2ce3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>laherparepvecBreast </prefix><exact>NCT02658812</exact><postfix> 2Talimogene laherpa</postfix><tags><tag><name>NCT02658812</name><uri>http://identifiers.org/clinicaltrials/NCT02658812</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-e839195443710a28ca8f82343dfdaec7</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>mbrolizumabMelanoma </prefix><exact>NCT02263508</exact><postfix> 1b/3Talimogene lahe</postfix><tags><tag><name>NCT02263508</name><uri>http://identifiers.org/clinicaltrials/NCT02263508</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-7733568e111d7b96adfeb409d7b59820</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�pembrolizumabSCCHN </prefix><exact>NCT02626000</exact><postfix> 1b/3Talimogene lahe</postfix><tags><tag><name>NCT02626000</name><uri>http://identifiers.org/clinicaltrials/NCT02626000</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-5ff993fd38ff48b321fa14af58c86fdf</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> ipilimumabMelanoma</prefix><exact>NCT02173171</exact><postfix>1b/2Talimogene laher</postfix><tags><tag><name>NCT02173171</name><uri>http://identifiers.org/clinicaltrials/NCT02173171</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-dbb3c6644d89f657076620cba15f5ee0</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�ipilimumabMelanoma </prefix><exact>NCT01740297</exact><postfix> 1b/2Talimogene lahe</postfix><tags><tag><name>NCT01740297</name><uri>http://identifiers.org/clinicaltrials/NCT01740297</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-97452a6356b052408753beaaf212d233</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>+ paclitaxelBreast </prefix><exact>NCT02779855</exact><postfix> 1/2Talimogene laher</postfix><tags><tag><name>NCT02779855</name><uri>http://identifiers.org/clinicaltrials/NCT02779855</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-873c4013ec4e50fd1d945df19f9a4bb1</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>Soft tissue sarcoma </prefix><exact>NCT02453191</exact><postfix> 1/2Talimogene laher</postfix><tags><tag><name>NCT02453191</name><uri>http://identifiers.org/clinicaltrials/NCT02453191</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-eaa71e8c32f5c1500ed7c8372460713e</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>erparepvecPancreatic</prefix><exact>NCT00402025</exact><postfix>1Talimogene laherpar</postfix><tags><tag><name>NCT00402025</name><uri>http://identifiers.org/clinicaltrials/NCT00402025</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-09db495b3f4c784b255c587aae5183a1</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ne laherparepvecHCC </prefix><exact>NCT02509507</exact><postfix> 1 Seprehvir (HSV17</postfix><tags><tag><name>NCT02509507</name><uri>http://identifiers.org/clinicaltrials/NCT02509507</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-06f3a2a02086aa908e2b822a9f42079c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>HSV1716Mesothelioma </prefix><exact>NCT01721018</exact><postfix> 1/2aHSV1716Solid tu</postfix><tags><tag><name>NCT01721018</name><uri>http://identifiers.org/clinicaltrials/NCT01721018</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8068c53ce7b4cbe2032b70b148c6ddca</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>HSV1716Solid tumors </prefix><exact>NCT00931931</exact><postfix> 1 HF10HSV-1None (w</postfix><tags><tag><name>NCT00931931</name><uri>http://identifiers.org/clinicaltrials/NCT00931931</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-cf905a5f89afe0d335d3aa5aaaecec00</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�ipilimumabMelanoma </prefix><exact>NCT02272855</exact><postfix> 2HF10HNC, SCC, brea</postfix><tags><tag><name>NCT02272855</name><uri>http://identifiers.org/clinicaltrials/NCT02272855</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-d2e983ef5391ac83ae2a59ba2ab4b555</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>CC, breast, melanoma</prefix><exact>NCT01017185</exact><postfix>1HF10Solid tumors NC</postfix><tags><tag><name>NCT01017185</name><uri>http://identifiers.org/clinicaltrials/NCT01017185</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-c8ac9bd63064ab27c337d27d0b2c0562</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>851HF10Solid tumors </prefix><exact>NCT02428036</exact><postfix> 1 ParvOryx (Parvov</postfix><tags><tag><name>NCT02428036</name><uri>http://identifiers.org/clinicaltrials/NCT02428036</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-14b2c400c62a8081efd242214d451b85</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>iedH-1PVGlioblastoma</prefix><exact>NCT01301430</exact><postfix>1/2aH-1PVPancreatic </postfix><tags><tag><name>NCT01301430</name><uri>http://identifiers.org/clinicaltrials/NCT01301430</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-37ec5c823bd8e43caed0aa62a1002c57</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>1/2aH-1PVPancreatic </prefix><exact>NCT02653313</exact><postfix> 1/2 JX-594/PexaVEC</postfix><tags><tag><name>NCT02653313</name><uri>http://identifiers.org/clinicaltrials/NCT02653313</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8e40dfd3de4ef76f57b5450691b8bb19</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ec + sorafenibHCC </prefix><exact>NCT02562755</exact><postfix> 3PexaVecHCCNCT01387</postfix><tags><tag><name>NCT02562755</name><uri>http://identifiers.org/clinicaltrials/NCT02562755</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-206d9cece0326ea857390e415fcbb2cc</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>02562755 3PexaVecHCC</prefix><exact>NCT01387555</exact><postfix>2bPexaVecCRCNCT01394</postfix><tags><tag><name>NCT01387555</name><uri>http://identifiers.org/clinicaltrials/NCT01387555</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-4ca07fdebd397e6564bab8a631148da3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>013875552bPexaVecCRC</prefix><exact>NCT01394939</exact><postfix>1/2aPexaVec + cycl</postfix><tags><tag><name>NCT01394939</name><uri>http://identifiers.org/clinicaltrials/NCT01394939</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-b14ed8d1d5f0904793186261dfd3b1b3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rs, sarcoma, breast </prefix><exact>NCT02630368</exact><postfix> 1/2PexaVecMelanoma,</postfix><tags><tag><name>NCT02630368</name><uri>http://identifiers.org/clinicaltrials/NCT02630368</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-2df350b424c9e034ddcb04eb29ec6c28</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ma, lung, RCC, HNSCC</prefix><exact>NCT00625456</exact><postfix>1PexaVecPediatric so</postfix><tags><tag><name>NCT00625456</name><uri>http://identifiers.org/clinicaltrials/NCT00625456</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-f242a5bd07932cd817ea86cd58fbaf3b</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>diatric solid tumors</prefix><exact>NCT01169584</exact><postfix>1 GL-ONC1VacciniaLu</postfix><tags><tag><name>NCT01169584</name><uri>http://identifiers.org/clinicaltrials/NCT01169584</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-b1a83d2a34737c27a744a58392af1692</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>aseGL-ONC1Peritoneal</prefix><exact>NCT01443260</exact><postfix>1/2GL-ONC1Solid tumo</postfix><tags><tag><name>NCT01443260</name><uri>http://identifiers.org/clinicaltrials/NCT01443260</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-161c228f5cd868e931ce91f3c5fecaca</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>GL-ONC1Solid tumors </prefix><exact>NCT02714374</exact><postfix> 1bGL-ONC1Peritoneal</postfix><tags><tag><name>NCT02714374</name><uri>http://identifiers.org/clinicaltrials/NCT02714374</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-7aa467dc2a57cef0bf138816d90320b3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ian, fallopian tube </prefix><exact>NCT02759588</exact><postfix> 1bGL-ONC1Lung NCT01</postfix><tags><tag><name>NCT02759588</name><uri>http://identifiers.org/clinicaltrials/NCT02759588</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-18b0979344941c2e8da98522659ba32c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>59588 1bGL-ONC1Lung </prefix><exact>NCT01766739</exact><postfix> 1GL-ONC1HNCNCT01584</postfix><tags><tag><name>NCT01766739</name><uri>http://identifiers.org/clinicaltrials/NCT01766739</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-76083b8d3662c70afddb481834809a79</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>01766739 1GL-ONC1HNC</prefix><exact>NCT01584284</exact><postfix>1GL-ONC1Solid tumors</postfix><tags><tag><name>NCT01584284</name><uri>http://identifiers.org/clinicaltrials/NCT01584284</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-c5b31e8a472d6714329497ef21b6a2d0</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>1GL-ONC1Solid tumors</prefix><exact>NCT00794131</exact><postfix>1 CG0070AdenovirusG</postfix><tags><tag><name>NCT00794131</name><uri>http://identifiers.org/clinicaltrials/NCT00794131</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-9aeb325b0b593805c7038bea6fdd536a</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>GM-CSFCG0070Bladder </prefix><exact>NCT02365818</exact><postfix> 3CG0070BladderNCT01</postfix><tags><tag><name>NCT02365818</name><uri>http://identifiers.org/clinicaltrials/NCT02365818</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-56e72ec296e446127dcbdd90bce2c646</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>65818 3CG0070Bladder</prefix><exact>NCT01438112</exact><postfix>2/3CG0070BladderNCT0</postfix><tags><tag><name>NCT01438112</name><uri>http://identifiers.org/clinicaltrials/NCT01438112</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-4b04cf6a16bc8244f2c8c0474be0728f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>81122/3CG0070Bladder</prefix><exact>NCT02143804</exact><postfix>2 VCN-01AdenovirusP</postfix><tags><tag><name>NCT02143804</name><uri>http://identifiers.org/clinicaltrials/NCT02143804</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-c19c333e3e679cf50f4e5499ed5235fe</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>d tumors, pancreatic</prefix><exact>NCT02045602</exact><postfix>1VCN-01 + gemcitab</postfix><tags><tag><name>NCT02045602</name><uri>http://identifiers.org/clinicaltrials/NCT02045602</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-e51e4fb02a0a791fa74995764f447877</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�abraxanePancreatic </prefix><exact>NCT02045589</exact><postfix> 1 DNX-2401Adenovir</postfix><tags><tag><name>NCT02045589</name><uri>http://identifiers.org/clinicaltrials/NCT02045589</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-14348c5b0f7cc333d937eaa2fd1fe113</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>umors, glioblastoma </prefix><exact>NCT02798406</exact><postfix> 2DNX-2401 + IFN-�</postfix><tags><tag><name>NCT02798406</name><uri>http://identifiers.org/clinicaltrials/NCT02798406</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-d4bee8604df226b8af9da211e428aef2</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>astoma, gliosarcoma </prefix><exact>NCT02197169</exact><postfix> 1bDNX-2401 + temo</postfix><tags><tag><name>NCT02197169</name><uri>http://identifiers.org/clinicaltrials/NCT02197169</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-4740b7ba9a51c167f8ba2d370119b9ec</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>zolomideGlioblastoma</prefix><exact>NCT01956734</exact><postfix>1 Delta-24-RGDAdeno</postfix><tags><tag><name>NCT01956734</name><uri>http://identifiers.org/clinicaltrials/NCT01956734</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8617424d5921f8c3ae9e35995782b1b6</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>a-24-RGDGlioblastoma</prefix><exact>NCT01582516</exact><postfix>1/2 EnadenotucirevA</postfix><tags><tag><name>NCT01582516</name><uri>http://identifiers.org/clinicaltrials/NCT01582516</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-6274addc9a05ac8a16756ddbf39c3fea</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>adenotucirevOvarian </prefix><exact>NCT02028117</exact><postfix> 1/2EnadenotucirevSo</postfix><tags><tag><name>NCT02028117</name><uri>http://identifiers.org/clinicaltrials/NCT02028117</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-037206293e3acf1b4d6391c9b0fb0c9c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>mors, mCRC, bladder </prefix><exact>NCT02028442</exact><postfix> 1/2Enadenotucirev </postfix><tags><tag><name>NCT02028442</name><uri>http://identifiers.org/clinicaltrials/NCT02028442</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-5510b51f5a148993aa5a21462c751afb</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>CHN, salivary gland </prefix><exact>NCT02636036</exact><postfix> 1 ONCOS-102Adenovi</postfix><tags><tag><name>NCT02636036</name><uri>http://identifiers.org/clinicaltrials/NCT02636036</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-d7c0559ca5d5b1367f4097c49207b366</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>NCOS-102Solid tumors</prefix><exact>NCT01598129</exact><postfix>1RNA viruses MG1MA3</postfix><tags><tag><name>NCT01598129</name><uri>http://identifiers.org/clinicaltrials/NCT01598129</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-bf165e65593950bb7a588c71624e30f7</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>3MG1MA3Solid tumors </prefix><exact>NCT02285816</exact><postfix> 1/2 VSV-IFN-betaVe</postfix><tags><tag><name>NCT02285816</name><uri>http://identifiers.org/clinicaltrials/NCT02285816</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-188bd122c78cd11cba6596240e4f94ff</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>FN-βVSV-IFN-betaHCC</prefix><exact>NCT01628640</exact><postfix>1 ReolysinReovirusN</postfix><tags><tag><name>NCT01628640</name><uri>http://identifiers.org/clinicaltrials/NCT01628640</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-77bc58daab50c9fb86153a2082d2a972</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> + paclitaxelSCCHN</prefix><exact>NCT01166542</exact><postfix>3Reolysin + pemetr</postfix><tags><tag><name>NCT01166542</name><uri>http://identifiers.org/clinicaltrials/NCT01166542</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-16748de5fbebd7ca7dd30bc205f04e78</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ed or docetaxelNSCLC</prefix><exact>NCT01708993</exact><postfix>2Reolysin + doceta</postfix><tags><tag><name>NCT01708993</name><uri>http://identifiers.org/clinicaltrials/NCT01708993</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-3c28f0258fd4e38578eacaed7f9ad542</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> prednisoneProstate</prefix><exact>NCT01619813</exact><postfix>2Reolysin + bevaci</postfix><tags><tag><name>NCT01619813</name><uri>http://identifiers.org/clinicaltrials/NCT01619813</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-88b605505d2671e8a05ae74d83dd9cbb</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>zumab + FOLFOXCRC </prefix><exact>NCT01622543</exact><postfix> 2Reolysin + carbo</postfix><tags><tag><name>NCT01622543</name><uri>http://identifiers.org/clinicaltrials/NCT01622543</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-39e0cc158c6f2238e0d93f2f077c4b31</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> paclitaxelMelanoma</prefix><exact>NCT00984464</exact><postfix>2Reolysin + carbop</postfix><tags><tag><name>NCT00984464</name><uri>http://identifiers.org/clinicaltrials/NCT00984464</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-aa4e7a4dc32ea5f72998dc9601fc7f24</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> + paclitaxelNSCLC</prefix><exact>NCT00861627</exact><postfix>2Reolysin + paclit</postfix><tags><tag><name>NCT00861627</name><uri>http://identifiers.org/clinicaltrials/NCT00861627</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-03873e6aae9ef7b84651979b739b5402</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ovarian, peritoneal </prefix><exact>NCT01199263</exact><postfix> 2Reolysin + pacli</postfix><tags><tag><name>NCT01199263</name><uri>http://identifiers.org/clinicaltrials/NCT01199263</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8c338361f8dbc3efdb524841a8937c65</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>+ paclitaxelBreast </prefix><exact>NCT01656538</exact><postfix> 2Reolysin + chemo</postfix><tags><tag><name>NCT01656538</name><uri>http://identifiers.org/clinicaltrials/NCT01656538</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-64dc764613a654d13d77f0b70c25f090</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rolizumabPancreatic </prefix><exact>NCT02620423</exact><postfix> 1bReolysin + chem</postfix><tags><tag><name>NCT02620423</name><uri>http://identifiers.org/clinicaltrials/NCT02620423</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-2eb992028583c8596cc87f1e173acc96</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ab KRAS mutant mCRC </prefix><exact>NCT01274624</exact><postfix> 1Reolysin + gemci</postfix><tags><tag><name>NCT01274624</name><uri>http://identifiers.org/clinicaltrials/NCT01274624</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-5317c14911d8b7d7bf1b8de6cf78c368</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>+ cisplatinBladder </prefix><exact>NCT02723838</exact><postfix> 1bReolysin + chem</postfix><tags><tag><name>NCT02723838</name><uri>http://identifiers.org/clinicaltrials/NCT02723838</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-de985e60e2b676805d2fd5979404a3ad</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ab KRAS mutant mCRC </prefix><exact>NCT01274624</exact><postfix> 1 NDV-HUJNewcastle</postfix><tags><tag><name>NCT01274624</name><uri>http://identifiers.org/clinicaltrials/NCT01274624</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-377cf2226194330f5fda74b44dafaf7c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rcoma, neuroblastoma</prefix><exact>NCT01174537</exact><postfix>1/2 MV-NISMeasles v</postfix><tags><tag><name>NCT01174537</name><uri>http://identifiers.org/clinicaltrials/NCT01174537</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-a490edf8e401f4f13586b956b9cab70d</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>porterMV-NISMyeloma </prefix><exact>NCT02192775</exact><postfix> 2MV-NIS + gemcita</postfix><tags><tag><name>NCT02192775</name><uri>http://identifiers.org/clinicaltrials/NCT02192775</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-ab56a19109904be9621452d2fd99d4e6</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>llopian, peritoneal </prefix><exact>NCT02364713</exact><postfix> 2MV-NIS + cycloph</postfix><tags><tag><name>NCT02364713</name><uri>http://identifiers.org/clinicaltrials/NCT02364713</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-59c0bb7835f971efcde79886107cace1</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ophosphamideMyeloma </prefix><exact>NCT00450814</exact><postfix> 1/2MV-NISOvarian, p</postfix><tags><tag><name>NCT00450814</name><uri>http://identifiers.org/clinicaltrials/NCT00450814</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-ddc32de01361eae7ab7ed92364f2bc16</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>Ovarian, peritoneal </prefix><exact>NCT02068794</exact><postfix> 1/2MV-NISHNSCC, bre</postfix><tags><tag><name>NCT02068794</name><uri>http://identifiers.org/clinicaltrials/NCT02068794</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-b67d38a776c63a5040326ab7b9f8e055</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>MV-NISHNSCC, breast </prefix><exact>NCT01846091</exact><postfix> 1MV-NISMesothelioma</postfix><tags><tag><name>NCT01846091</name><uri>http://identifiers.org/clinicaltrials/NCT01846091</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-467d477e964aa1cf7f8587d704b178ee</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>1MV-NISMesothelioma </prefix><exact>NCT01503177</exact><postfix> 1MV-NISGlioblastoma</postfix><tags><tag><name>NCT01503177</name><uri>http://identifiers.org/clinicaltrials/NCT01503177</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-fdcf2d1270cf1472887068f59db4eb85</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>1MV-NISGlioblastoma </prefix><exact>NCT00390299</exact><postfix> 1MV-NISOvarian, per</postfix><tags><tag><name>NCT00390299</name><uri>http://identifiers.org/clinicaltrials/NCT00390299</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-cb5be3ad5b5bf5639a39d5a1b7e93a48</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>SOvarian, peritoneal</prefix><exact>NCT00408590</exact><postfix>1MV-NISPeripheral ne</postfix><tags><tag><name>NCT00408590</name><uri>http://identifiers.org/clinicaltrials/NCT00408590</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-a7b4cea35b4a678946f66ea737029d5f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>pheral nerve sheath </prefix><exact>NCT02700230</exact><postfix> 1 SVV-01Seneca Val</postfix><tags><tag><name>NCT02700230</name><uri>http://identifiers.org/clinicaltrials/NCT02700230</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-fc59f25559800711f8bfbe65a0992e8c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix> specifiedSVV-01Lung</prefix><exact>NCT01017601</exact><postfix>2SVV-01Neuroendocrin</postfix><tags><tag><name>NCT01017601</name><uri>http://identifiers.org/clinicaltrials/NCT01017601</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-a9c54ca2c8d7bb9678e3f74c9cb84cbe</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>SVV-01Neuroendocrine</prefix><exact>NCT00314925</exact><postfix>1SVV-01Neuroblastoma</postfix><tags><tag><name>NCT00314925</name><uri>http://identifiers.org/clinicaltrials/NCT00314925</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-2a7dc72de068c9471246ac6fd878057e</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>oma, sarcoma, kidney</prefix><exact>NCT01048892</exact><postfix>1 CVA21 (Cavatak)Co</postfix><tags><tag><name>NCT01048892</name><uri>http://identifiers.org/clinicaltrials/NCT01048892</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-c92298137141cbe7cb8ee1a5afe98a6f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>rusNoneCVA21Melanoma</prefix><exact>NCT01227551</exact><postfix>2CVA21MelanomaNCT016</postfix><tags><tag><name>NCT01227551</name><uri>http://identifiers.org/clinicaltrials/NCT01227551</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-4a1461694a0333cf166193c2c592919c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>2275512CVA21Melanoma</prefix><exact>NCT01636882</exact><postfix>2CVA21 + ipilimuma</postfix><tags><tag><name>NCT01636882</name><uri>http://identifiers.org/clinicaltrials/NCT01636882</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-49b12e8ecb6de8e4334618df01ad6f5f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�ipilimumabMelanoma </prefix><exact>NCT02307149</exact><postfix> 1bCVA21 + pembrol</postfix><tags><tag><name>NCT02307149</name><uri>http://identifiers.org/clinicaltrials/NCT02307149</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-54b902bdeefd4238cbfea547b98f9bf7</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>, melanoma, bladder </prefix><exact>NCT02043665</exact><postfix> 1CVA21Melanoma, bre</postfix><tags><tag><name>NCT02043665</name><uri>http://identifiers.org/clinicaltrials/NCT02043665</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-19074fb19412ae7d122b9579a6a29ee1</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ma, breast, prostate</prefix><exact>NCT00636558</exact><postfix>1CVA21MelanomaNCT004</postfix><tags><tag><name>NCT00636558</name><uri>http://identifiers.org/clinicaltrials/NCT00636558</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8e693d8fc961fb14f44a7c15d41f2cf7</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>6365581CVA21Melanoma</prefix><exact>NCT00438009</exact><postfix>1CVA21HNCNCT00832559</postfix><tags><tag><name>NCT00438009</name><uri>http://identifiers.org/clinicaltrials/NCT00438009</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-db09a50da8586fb0b8d1583784ea5eca</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>NCT004380091CVA21HNC</prefix><exact>NCT00832559</exact><postfix>1CVA21 + mitomycin</postfix><tags><tag><name>NCT00832559</name><uri>http://identifiers.org/clinicaltrials/NCT00832559</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-4d99988cc8a88885cafa00ba627b84a3</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>�mitomycin CBladder </prefix><exact>NCT02316171</exact><postfix> 1CVA21 + pembroli</postfix><tags><tag><name>NCT02316171</name><uri>http://identifiers.org/clinicaltrials/NCT02316171</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-dfd2bf0595101d067f1273440df987d7</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>mbrolizumabMelanoma </prefix><exact>NCT02565992</exact><postfix> 1 PVS-RIPOPoliovir</postfix><tags><tag><name>NCT02565992</name><uri>http://identifiers.org/clinicaltrials/NCT02565992</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-8b7266cad58acec117fbd46daa48807f</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>VS-RIPOGlioblastoma </prefix><exact>NCT01491893</exact><postfix> 1PVS-RIPO + lomus</postfix><tags><tag><name>NCT01491893</name><uri>http://identifiers.org/clinicaltrials/NCT01491893</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-92e6177d4cf560a936c94c961ee72bb9</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>ineMalignant glioma </prefix><exact>NCT02986178</exact><postfix> 2PVS-RIPOMalignant </postfix><tags><tag><name>NCT02986178</name><uri>http://identifiers.org/clinicaltrials/NCT02986178</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-5d2d6b6331c8d07325ce573097344a62</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>IPOMalignant glioma </prefix><exact>NCT03043391</exact><postfix> 1 CNS central nervo</postfix><tags><tag><name>NCT03043391</name><uri>http://identifiers.org/clinicaltrials/NCT03043391</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-ff671d2e82b8219a1ff30d7a6a46196c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation><annotation><prefix>als.gov identifier, </prefix><exact>NCT01166542</exact><postfix>); however, it must </postfix><tags><tag><name>NCT01166542</name><uri>http://identifiers.org/clinicaltrials/NCT01166542</uri></tag></tags><id>http://europepmc.org/articles/PMC5626801#europepmc-483f4d122b7812df6a58dc447873651c</id><type>Accession Numbers</type><section>Article (http://semanticscience.org/resource/SIO_001029)</section><provider>Europe PMC</provider><subType>NCT</subType></annotation></annotations></item></List>